Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Wave Life Sciences (WVE) over the last 11 years, with Q3 2025 value amounting to $196.2 million.

  • Wave Life Sciences' Cash & Equivalents fell 3689.68% to $196.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $196.2 million, marking a year-over-year decrease of 3689.68%. This contributed to the annual value of $302.1 million for FY2024, which is 5077.44% up from last year.
  • Latest data reveals that Wave Life Sciences reported Cash & Equivalents of $196.2 million as of Q3 2025, which was down 3689.68% from $208.5 million recorded in Q2 2025.
  • Wave Life Sciences' Cash & Equivalents' 5-year high stood at $310.9 million during Q3 2024, with a 5-year trough of $88.5 million in Q4 2022.
  • Moreover, its 5-year median value for Cash & Equivalents was $154.0 million (2024), whereas its average is $176.5 million.
  • In the last 5 years, Wave Life Sciences' Cash & Equivalents tumbled by 4273.51% in 2021 and then soared by 12639.3% in 2023.
  • Quarter analysis of 5 years shows Wave Life Sciences' Cash & Equivalents stood at $150.6 million in 2021, then tumbled by 41.22% to $88.5 million in 2022, then surged by 126.39% to $200.4 million in 2023, then soared by 50.77% to $302.1 million in 2024, then tumbled by 35.04% to $196.2 million in 2025.
  • Its Cash & Equivalents stands at $196.2 million for Q3 2025, versus $208.5 million for Q2 2025 and $243.1 million for Q1 2025.